Trial Profile

A Multicenter Open Label Study on the Safety and Efficacy of Deflazacort (Emflaza®) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deflazacort (Primary)
Indications Limb girdle muscular dystrophies
Focus Registrational; Therapeutic Use
Sponsors PTC Therapeutics

Most Recent Events

19 Feb 2021 This trial was completed in Denmark (end date: 2021-01-15).
17 Feb 2021 Status changed from active, no longer recruiting to completed.
08 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com